Study Demonstrates Lexapro Improves Adolescent Depression SymptomsForest Laboratories has completed a study that shows Lexapro improved symptoms of adolescent depression as compared with placebo.
Read More
Novartis Vaccine Successful Against Meningitis in Phase III TrialNovartis’ meningitis vaccine Menveo may offer greater protection for adolescents than sanofi pasteur’s Menactra based on results of a pivotal Phase III clinical trial, the company says.
Read More
Trubion Starts Phase IIb Study for Rheumatoid Arthritis TreatmentTrubion Pharmaceuticals and its partner, Wyeth Pharmaceuticals, have begun patient dosing in the next Phase IIb clinical trial of TRU-015 in patients with rheumatoid arthritis (RA).
Read More
Cleveland BioLabs Completes Recruitment for Prostate Cancer TrialCleveland BioLabs has enrolled all the patients in its Phase II clinical trial of Curaxin CBLC102 in advanced, hormone-refractory prostate cancer.
Read More
Argos Initiates Phase II Trial for HIV ImmunotherapyArgos Therapeutics will begin a Phase IIa proof-of-concept clinical trial to test the efficacy of its AGS-004 therapy to improve immune control of viral replication in HIV-infected adults.
Read More
Amylin Initiates Phase IIb Obesity StudyAmylin Pharmaceuticals has begun a Phase IIb study evaluating various dosing combinations of pramlintide, an analog of the natural hormone amylin, and recombinant human leptin for the treatment of obesity.
Read More
Nventa Announces Positive Data From Phase I Cervical Dysplasia TrialNventa Biopharmaceuticals says it achieved positive immunological data in its ongoing Phase I clinical trial of its therapeutic product candidate HspE7 for patients with cervical intraepithelial neoplasia, a precursor to cervical cancer.
Read More
Velcura Therapeutics Reports Successful Phase I Trial of Bone Disease TherapyVelcura Therapeutics has successfully completed a first-in-human clinical trial for its lead compound VEL-0230, which the company is investigating as a treatment for rheumatoid arthritis (RA) and other bone diseases, it says.
Read More
VGX Signs Agreement With UK Cystic Fibrosis Gene Therapy ConsortiumVGX Pharmaceuticals has signed a multiyear agreement to provide plasmid DNA to support the ongoing toxicology and clinical trials of the UK Cystic Fibrosis Gene Therapy Consortium.
Read More
Pipex Gets Orphan Designation for Idiopathic Pulmonary Fibrosis TreatmentPipex Pharmaceuticals received orphan drug designation from the FDA for its oral treatment for idiopathic pulmonary fibrosis (IPF), a deadly pulmonary disease.
Read More
|
Shopping Cart
Your shopping cart is empty
|
